- Home
- DAWN vs FIP Comparison
DAWN vs FIP Comparison
Compare DAWN & FIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- FIP
- Stock Information
- Founded
- DAWN 2018
- FIP 2021
- Country
- DAWN United States
- FIP United States
- Employees
- DAWN N/A
- FIP N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- FIP Consumer Electronics/Appliances
- Sector
- DAWN Health Care
- FIP Industrials
- Exchange
- DAWN Nasdaq
- FIP Nasdaq
- Market Cap
- DAWN 658.9M
- FIP 715.0M
- IPO Year
- DAWN 2021
- FIP N/A
- Fundamental
- Price
- DAWN $6.71
- FIP $6.27
- Analyst Decision
- DAWN Strong Buy
- FIP Buy
- Analyst Count
- DAWN 6
- FIP 1
- Target Price
- DAWN $30.17
- FIP $12.00
- AVG Volume (30 Days)
- DAWN 1.3M
- FIP 984.9K
- Earning Date
- DAWN 08-05-2025
- FIP 08-07-2025
- Dividend Yield
- DAWN N/A
- FIP 1.91%
- EPS Growth
- DAWN N/A
- FIP N/A
- EPS
- DAWN N/A
- FIP N/A
- Revenue
- DAWN $161,922,000.00
- FIP $345,123,000.00
- Revenue This Year
- DAWN $17.98
- FIP $65.61
- Revenue Next Year
- DAWN $49.50
- FIP $30.50
- P/E Ratio
- DAWN N/A
- FIP N/A
- Revenue Growth
- DAWN N/A
- FIP 5.70
- 52 Week Low
- DAWN $6.08
- FIP $3.10
- 52 Week High
- DAWN $16.76
- FIP $10.46
- Technical
- Relative Strength Index (RSI)
- DAWN 47.98
- FIP 46.86
- Support Level
- DAWN $6.32
- FIP $6.04
- Resistance Level
- DAWN $7.18
- FIP $7.18
- Average True Range (ATR)
- DAWN 0.29
- FIP 0.34
- MACD
- DAWN 0.01
- FIP -0.06
- Stochastic Oscillator
- DAWN 36.11
- FIP 31.70
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About FIP FTAI Infrastructure Inc.
FTAI Infrastructure Inc is engaged in five segments; Railroad segment includes five freight railroads and one switching company that provide rail service to certain manufacturing and production facilities, the Jefferson Terminal segment consists of a multi-modal crude oil and refined products terminal and other related assets. Repauno segment consists of a 1,630-acre deep-water port located along the Delaware River with an underground storage cavern, a new multipurpose dock, a rail-to-ship transloading system, and multiple industrial development opportunities. Power and Gas segment is comprised of an equity method investment in Long Ridge, and Sustainability and Energy Transition segment is comprised of Aleon/Gladieux, Clean Planet, and CarbonFree.